Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina

The Biomedical Networking Research Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) is one of the 11 thematic areas of CIBER. CIBER groups some of the main Spanish research groups (more than 400) in biomedicine, located in more than 100 institutions distributed around Spain.

Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0 28029 Madrid

Use of an inhibitor of adrenomedullin for the manufacture of a drug useful in the prevention and treatment of disease that reduce bone density

managed by CIBER-BBN

TECHNOLOGY DESCRIPTION

Scope of the problem:
Osteoporosis is a serious problem in the elderly population and is characterized by a decrease in bone mineral density (a T scale of mineral density lower than 2.5) and deterioration of bone micro architecture, which can lead to an increased risk of fractures. Osteoporosis is more common among women, especially after menopause. Estrogen deficiency increases the bone resorption process, causing the balance between bone deposition by osteoblasts and resorption by osteoclasts inclined to net bone loss. Many studies have shown that hormone replacement therapy can be used to prevent and/or treat osteoporosis. However, long-term estrogen supplementation has severe risks including endometrial cancer, breast cancer or ovarian cancer, as well as cardiovascular risks, so this treatment is no longer recommended.

Our innovation:

  • Use of inhibitor of adrenomedullin to manufacture a new drug for osteoporosis

  • Inhibitor is selected from the group consisting of the fragment of adrenomedullin AM22-52 and the compounds of formula described in the figure (see flyer)

  • Or polyclonal antibody, monoclonal antibody,nucleotide, peptide and vaccine.

  • Or interference RNA molecule,

  • It can be used in a state of weightlessness or in space travel

  • It can also be used in farm or domestic animal

BENEFITS

It can be also used in osteomalacia, rheumatoid arthritis, chronic kidney disease, hyperparathyroidism, Cushing’s disease, cystic fibrosis, eating disorders, gastric bypass and prolonged immobility.

LIMITATIONS

To be determined during further development.

APPLICATIONS

Patient need addressed: Osteoporosis

Readiness Level (TRL)

3
experimental proof of concept(The pie chart refers to the entire portfolio contained in the database of the helpdesk)

Technology Readiness Levels (TRL) are a method of estimating technology maturity of Critical Technology Elements (CTE) of a program during the acquisition process. The use of TRLs enables consistent, uniform, discussions of technical maturity across different types of technology.

Patent Grading Report

Patent Grading Report

The Grading Patents Report evaluates and grades US patents

Sample Buy from Wisdomain

STATUS

Current status

European patent application EP15382111.1

AVAILABILITY

Available for

Licensing or Assignment

INVENTOR / TEAM

Alfredo Martinez, M. Sonia Martinez, Ignacio Larráyoz, Laura Ochoa, Luis Jose Fernandez, Ignacio Ochoa

GENERAL ENQUIRIES
LICENSING REQUEST

Case manager: Aida Castellanos Paez

EU-Japan Centre
European CommissionMeti